I think Howie could change his tone with regards Sofdra being our number one focus in 2024. A little bit coy, very much focused but in my
opinion, not totally straight forward. Should the pent up demand result in a situation comparable to the demand for Ozempic - which is out of stock - and I just thought of an idea, why don't we market sofdra to those sweating on an out of stock pharmaceutical - then I have no doubt whatsoever that
some of the other phases will be back on the agenda in late 2024. Absolutely one hundred per cent folks.
BOT - Anything but charting, page-6966
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
0.005(1.54%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.5¢ | $842.1K | 2.564M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 1013227 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 110750 | 6 |
View Market Depth
| Last trade - 12.54pm 11/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |